TNFRSF11A and prostate cancer: Denosumab, a humanized RANKL antibody and the first drug of this class, has demonstrated superiority over ZOL in preventing bone diseases in both breast and prostate cancers with bone metastases.415,416 Denosumab prevents the RANKL/RANK interaction by mimicking the action of OPG and thus reduces the survival and bone resorption activity of these osteoclasts.417,418 Based on the overall satisfactory results of clinical trials, denosumab has now been approved for SRE prevention in patients with cancer.